The List of GLP-1 Medications, and Where Each One Is Approved (September 2026)

This is a reference page. Its only job is to list, with attribution, every GLP-1 receptor agonist and GIP/GLP-1 receptor agonist holding a marketing approval in at least one of seven jurisdictions as of 14 September 2026, so a person keeping their own medication record can see what each brand is and where it is approved.

It is not medical advice. It has not been written or reviewed by a clinician, it makes no recommendation about whether any medication suits anybody, and it does not compare efficacy, rank products, or say how much to take or when. Those decisions belong to the prescriber and the dispensing pharmacist.

Investigational compounds such as retatrutide, CagriSema and survodutide are not on the list, and neither are compounded copies, because no regulator has approved either.

Thirteen branded products, six molecules, grouped by molecule. Each line gives brand, molecule, manufacturer, route and cadence.

Ozempic: semaglutide, Novo Nordisk, subcutaneous injection, once weekly. Wegovy: semaglutide, Novo Nordisk, subcutaneous injection, once weekly. Wegovy HD: semaglutide, Novo Nordisk, subcutaneous injection, once weekly, the 7.2 mg strength listed in Section 3 of the Wegovy label. Wegovy pill: semaglutide, Novo Nordisk, oral tablet, once daily. Rybelsus: semaglutide, Novo Nordisk, oral tablet, once daily. Ozempic tablets: semaglutide, Novo Nordisk, oral tablet, once daily, United States only.

Mounjaro: tirzepatide, Eli Lilly, subcutaneous injection, once weekly. Zepbound: tirzepatide, Eli Lilly, subcutaneous injection, once weekly. Victoza: liraglutide, Novo Nordisk, subcutaneous injection, once daily. Saxenda: liraglutide, Novo Nordisk, subcutaneous injection, once daily. Trulicity: dulaglutide, Eli Lilly, subcutaneous injection, once weekly. Bydureon BCise: exenatide extended-release, AstraZeneca, subcutaneous injection, once weekly, being discontinued in the US. Foundayo: orforglipron, Eli Lilly, oral tablet, once daily.

Route and cadence come from each FDA label on DailyMed. Each molecule has its own pharmacokinetic page in this pillar, starting with Ozempic and Mounjaro; this page stops at the roster and the approvals.

Ozempic, Novo Nordisk's weekly injection, is the anchor. Its FDA label (DailyMed, revised May 2026) lists glycaemic control in adults with type 2 diabetes, cardiovascular risk reduction with established cardiovascular disease, and kidney outcomes with chronic kidney disease. The EMA authorised it on 8 February 2018; the UK emc lists it under Novo Nordisk Limited; Novo Nordisk Canada records a 2018 approval; the TGA has it registered for type 2 diabetes; Anvisa added a chronic kidney disease indication in February 2026, per Novo Nordisk Brasil. COFEPRIS: not verified.

Wegovy is the same molecule at weight-management strengths. Its FDA label (DailyMed, revised June 2026) covers cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, weight reduction in adults and pediatric patients aged 12 and older, and, under accelerated approval, non-cirrhotic MASH. The EMA authorised it on 6 January 2022; the UK SmPC on the emc adds cardiovascular risk reduction and MASH; Novo Nordisk Canada announced approval in November 2021; the TGA registered it on 1 September 2022; Anvisa approved it in January 2023 and added a cardiovascular indication in February 2026; Novo Nordisk's July 2026 Mexico announcement refers to the existing COFEPRIS approval of injectable Wegovy and adds MASH. See the Wegovy page.

Wegovy HD is Novo Nordisk's name for the 7.2 mg strength in Section 3 of the Wegovy label. The MHRA authorised it first, in January 2026; the FDA on 19 March 2026; the European Commission in March 2026, per Novo Nordisk's announcement following the CHMP opinion of 12 December 2025 (the announcement gives no decision date), with a single-dose 7.2 mg pen approved on 15 July 2026; Anvisa, announced by Novo Nordisk Brasil on 4 May 2026; COFEPRIS in July 2026, per Novo Nordisk. Health Canada and TGA: not verified. See Wegovy HD.

The Wegovy pill is oral semaglutide for weight management, listed on the same label as a 25 mg tablet alongside 1.5, 4 and 9 mg tablets. The FDA approved it on 22 December 2025, the MHRA on 11 June 2026, the European Commission on 15 July 2026, and COFEPRIS per Novo Nordisk's 18 August 2026 announcement. Novo Nordisk Brasil said in May 2026 its January submission was still under Anvisa review; Health Canada and TGA: not verified. See the Wegovy pill page.

Rybelsus is oral semaglutide for type 2 diabetes, first approved by the FDA in 2019 according to Novo Nordisk. The EMA authorised it on 3 April 2020; Health Canada in April 2020; the TGA on 7 February 2022; Anvisa lists it as registered and approved cardiovascular risk reduction on 27 April 2026, announced by Novo Nordisk Brasil on 28 April; the UK emc lists it in reformulated 1.5, 4 and 9 mg strengths with the original 3, 7 and 14 mg strengths marked discontinued. COFEPRIS: not verified. In the US, Novo Nordisk launched the reformulated tablets as Ozempic tablets on 4 May 2026. They share one DailyMed label with Rybelsus, revised January 2026, which still lists Rybelsus at its original 3, 7 and 14 mg strengths and states that the two are not substitutable on a mg-to-mg basis. Details on Rybelsus.

Tirzepatide is Eli Lilly's dual GIP and GLP-1 receptor agonist, and its brand depends on the country. In the US, Mounjaro's FDA label (DailyMed, revised July 2026) covers glycaemic control in adults and pediatric patients aged 10 and older with type 2 diabetes; Zepbound's label (revised August 2026) covers weight reduction in adults with obesity or overweight and moderate to severe obstructive sleep apnoea in adults with obesity. Both record an Initial U.S. Approval of 2022, the molecule's first.

Canada mirrors the split. Health Canada issued Mounjaro's Notice of Compliance for type 2 diabetes on 24 November 2022, later extended to children aged 10 and older; Zepbound was authorised for chronic weight management on 13 May 2025 and for obstructive sleep apnoea on 16 June 2026, per Lilly Canada.

In the EU, the UK, Australia and Brazil there is no Zepbound. The EMA authorised Mounjaro on 15 September 2022 and its EPAR lists both type 2 diabetes and weight management; the UK SmPC on the emc, revised 8 September 2026, carries the same two indications; the TGA registered the weight-management extension on 10 September 2024 after the type 2 diabetes registration of 23 December 2022; Anvisa approved the obesity and overweight indication on 9 June 2025, per Agência Brasil; and in Mexico, Lilly de México announced in May 2025 that tirzepatide, first approved by COFEPRIS for type 2 diabetes, was authorised in Mexico for weight control (the announcement does not name the regulator); neither Lilly de México release names Mounjaro or Zepbound, so the Mexican brand is recorded as not verified. See the Zepbound page and Mounjaro vs Zepbound.

Liraglutide is the once-daily molecule. Victoza, Novo Nordisk's type 2 diabetes brand, carries an FDA label (DailyMed, revised 14 October 2025) for glycaemic control in adults and pediatric patients aged 10 and older and cardiovascular risk reduction. The EMA authorised it on 30 June 2009; Health Canada's December 2024 Health Product InfoWatch lists it as marketed; the TGA registered it on 26 August 2010; Anvisa's own notice records a March 2010 approval. The UK emc listing for liraglutide on 14 September 2026 shows Saxenda, Xultophy and six generic liraglutide pens but no Victoza entry, so the UK brand status is recorded as not verified. COFEPRIS: not verified.

Saxenda is liraglutide at the weight-management strength; its FDA label (DailyMed, revised June 2026) covers weight reduction in adults and pediatric patients aged 12 and older. The EMA authorised it on 23 March 2015 and its EPAR now extends to children aged 6 and older; the UK emc lists it; Health Canada's InfoWatch lists it; the TGA registered it on 24 December 2015; Anvisa lists it with an adolescent indication added. COFEPRIS: not verified. See Saxenda and Victoza.

Dulaglutide is Trulicity, Eli Lilly's weekly injection. Its FDA label (DailyMed, revised March 2026, Initial U.S. Approval 2014) covers glycaemic control in adults and pediatric patients aged 10 and older and cardiovascular risk reduction. The EMA authorised it on 21 November 2014; the UK emc lists four strengths under Eli Lilly and Company Limited; Health Canada's InfoWatch lists it; the TGA has it on the ARTG; Anvisa extended it to patients aged 10 and older in 2023. COFEPRIS: not verified. See the Trulicity page.

Bydureon BCise is the oldest molecule on the list and the one leaving it. An FDA Office of Surveillance and Epidemiology review dated 14 April 2025 records that Byetta was first approved on 28 April 2005, Bydureon on 27 January 2012 (withdrawn from sale in March 2021) and Bydureon BCise on 20 October 2017, and that AstraZeneca notified the FDA on 16 August 2024 of its plan to permanently discontinue marketing Byetta and Bydureon BCise. The EMA's EPAR for Bydureon, authorised 17 June 2011, still shows it as authorised for type 2 diabetes. The UK emc returned no exenatide product on 14 September 2026, Health Canada's December 2024 InfoWatch does not list it, and the TGA, Anvisa and COFEPRIS positions are not verified. See the Bydureon BCise page.

Foundayo is the newest. Orforglipron is a non-peptide small molecule; Eli Lilly's announcement of 1 April 2026 records FDA approval for adults with obesity or overweight with a weight-related condition, and the MHRA authorised it on 10 August 2026 for weight management and type 2 diabetes, the first authorisation in Europe according to GOV.UK. Lilly's second-quarter 2026 report lists the US type 2 diabetes submission as completed but not approved, and Lilly says the medicine is submitted in more than 40 countries. European Commission, Health Canada, TGA, Anvisa and COFEPRIS: not verified. See the Foundayo page.

One molecule belongs in a footnote. Sanofi's lixisenatide (Lyxumia in the EU) was authorised by the EMA on 31 January 2013 and withdrawn on 18 December 2025 at Sanofi's request for commercial reasons; the fixed-ratio combination Soliqua still appears on Health Canada's marketed list.

Read by regulator rather than by brand, the picture on 14 September 2026 is this.

United States (FDA): every product on the list, including the Wegovy pill, Wegovy HD, Ozempic tablets and Foundayo; Bydureon BCise is approved but being discontinued by its manufacturer, and Zepbound rather than Mounjaro carries the weight-management and sleep apnoea indications.

European Union (EMA): Ozempic, Wegovy including Wegovy HD and the pill, Rybelsus, Mounjaro with both indications, Victoza, Saxenda, Trulicity and Bydureon. No Zepbound, no Ozempic tablets, and no Foundayo decision yet.

United Kingdom (MHRA, with the emc as the SmPC record): Ozempic, Wegovy including Wegovy HD and the tablets, Rybelsus in reformulated strengths, Mounjaro with both indications, Saxenda, Trulicity and Foundayo. Victoza and exenatide: not verified.

Canada (Health Canada): Ozempic, Wegovy, Rybelsus, Mounjaro for type 2 diabetes, Zepbound for weight management and sleep apnoea, Victoza, Saxenda, Trulicity, plus generic semaglutide since April 2026. Wegovy pill, Wegovy HD, Foundayo and Bydureon BCise: not verified.

Australia (TGA): Ozempic, Wegovy, Rybelsus, Mounjaro with both indications, Victoza, Saxenda and Trulicity. Wegovy pill, Wegovy HD, Foundayo and Bydureon BCise: not verified.

Brazil (Anvisa): Ozempic, Wegovy including Wegovy HD, Rybelsus, Mounjaro with both indications, Victoza, Saxenda, Trulicity, EMS's Ozivy (registered as a new synthetic semaglutide product, not a generic, per Anvisa) since 26 May 2026, and Brazil's first generic semaglutide pen from EMS and Germed's similar Semaclique, both registered with Ozivy as their reference product, since 17 August 2026. Wegovy pill under review per Novo Nordisk Brasil; Foundayo and Bydureon BCise: not verified.

Mexico (COFEPRIS): tirzepatide (brand not verified) for type 2 diabetes per Lilly México's 2023 release, and for weight control per Lilly de México's May 2025 announcement, which does not name the regulator, Wegovy including Wegovy HD and MASH, and the Wegovy pill. Ozempic, Rybelsus, Victoza, Saxenda, Trulicity, Foundayo and Bydureon BCise: not verified, meaning not traced to a primary document, not that they are unavailable.

Regulators revise, withdraw and extend. Where this page conflicts with a current label or listing, the current document wins.

The list is starting to include products that are not brands. Health Canada announced on 29 June 2026 that it had authorised Apotex's Sevmia, a once-weekly generic semaglutide for chronic weight management in patients aged 12 and older, after a generic for type 2 diabetes on 1 May 2026 and a first Canadian generic on 28 April 2026, with six more submissions under review. Anvisa registered EMS's Ozivy on 26 May 2026 as a new drug, a synthetic analogue of Ozempic; Reuters' headline called it Brazil's first generic semaglutide pen, but Anvisa's own notice of 27 May 2026 states that Ozivy is not a generic, because Brazilian regulation has no generic versions of biological products. The first Brazilian generic came on 17 August 2026: Anvisa's notice of that date announced two further once-weekly semaglutide pens for type 2 diabetes, an unnamed EMS generic and Germed's similar Semaclique, registered as interchangeable with Ozivy as their reference product; Exame reports the resolution was signed on 13 August and published in the Diário Oficial da União on 17 August, and the Conselho Federal de Farmácia carried the same registration. In the US, the FDA approved the first generic liraglutide referencing Victoza (Hikma) on 23 December 2024, per the FDA's announcement, and Teva's generic referencing Saxenda on 28 August 2025, per Teva's announcement as reported by BioSpace. Compounded semaglutide and tirzepatide are absent because no regulator has approved them; the compounded semaglutide guide explains the distinction.

For someone keeping their own record, the practical point is that brand, molecule and strength are three different facts, and a log is only useful if it captures all three exactly as printed on the box. GLP-1 Tracker, free to download on iPhone, records the medication name you choose, the strength you were prescribed, each dose date, the injection site, your weight trend and the meals you photograph, on your device without an account. It does not decide which product you are on or generate a schedule; if you switch brands or countries, the how-to on switching medications shows what to write down so the history stays legible to the prescriber.